Sprycel Articles
Mixed NICE recommendations for CML and diabetes drugs
13 January 2012
UK NICE recommends Novartis drugs for chronic myeloid leukemia, but not Bristol-Myers’ Sprycel
6 December 2011
UK’s NICE asks for more info on Boehringer’s Pradaxa; backs Novartis’ Tasigna but not Glivec or B-MS Sprycel for leukemia
18 August 2011
ASCO highlights include GSK’s pazopanib, Novartis’ INC424 and Glivec, B-MS/Otsuka’s Sprycel
6 June 2011
European Commission clears Bristol-Myers’s Sprycel for additional use in newly-diagnosed CML
9 December 2010
Celgene plunges on concerns of secondary malignancies with blockbuster multiple myeloma drug Revlimid; news from Novo Nordisk, B-MS at ASH
7 December 2010
US FDA approves additional medical indication for Bristol-Myers Squibb’s Sprycel; clears Sunovion’s Latuda; further delays Vivus’ Qnexa
29 October 2010
Bristol-Myers/Otsuka get US FDA priority review for Sprycel in chronic myeloid leukemia
13 July 2010
UK patient group makes case for CML drugs Sprycel and Tasigna given initial “thumbs down” by the NICE
24 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
FDA grants full approval to B-MS' Sprycel
27 May 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
Four Novartis drugs and B-MS
9 March 2009
CytRx reports strong early results for CML drug
17 November 2008
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
Wales' drug authority recommends Sprycel
28 January 2008
SMC approves S-P's Remicade in psoriasis
21 May 2007
ChemGenex completes A$21M financing
9 April 2007
BIO survey rebuts Part D price negotiation plan
5 March 2007
CML treatment Sprycel launched in UK
11 December 2006
B-MS' Sprycel approved for resistant CML
27 November 2006
Industry bodies oppose annual revision of Japan
7 August 2006
Sprycel gets expedited approval for CML
10 July 2006
B-M S's dasatinib shows promise in CML studies
26 June 2006
B-MS' dasatinib granted priority review by US FDA
13 March 2006
B-MS completes submission of dasatinib NDA
9 January 2006
B-MS announces cost-cutting plans
19 December 2005
Showing 1-47 of 47 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
